Search results for " capacity"
Article
Addressing the Complex Nature of Downstream Processing with QbD
“Polishing steps such as ion exchange, hydroxyapatite, and hydrophobic interaction chromatography can be more heavily influenced by pH, conductivity, loading capacity, residence time, and temperature,…
Article
Single-Use for Downstream Chromatography: Benefit or Hindrance?
Single-use technology is gaining ground in downstream bioprocessing, but challenges stall further adoption.
By Feliza Mirasol
ARTMOIS/STOCK.ADOBE.COM
Biopharmaceutical manufactu…
Article
What’s New in Upstream Technologies
The biomass capacity offers a broad measurement range and bubble correction factors for gas bubble density and enables reliable online measurements in high aeration and agitation environments. Online …
Article
Science Focus Fuels Successful Process Development for Startups
In fact, emerging biopharma firms working in the fields of cell and gene therapy face significant competition for contract manufacturing capacity, according to Krishnan. It is important to begin the s…
Article
Scalable Viral Vector Manufacturing
Furthermore, there is also a shortage in available manufacturing capacity within many companies as well as in contract manufacturers.
What are the main challenges for viral vector manufacturing? A…
Article
Understanding Validation and Technical Transfer, Part 2
Understanding Validation and Technical Transfer, Part 2
A validation plan developed to support a process unrelated to bio-pharmaceutical manufacture is applied to biopharmaceutical processes and sys…
Article
Understanding Validation and Technical Transfer, Part 3
System operating parameters and capacity should be determined, and operations should fall within the validated ranges.
Cell modification processes should be developed based on studies designed …
Article
Establishment of New Modern Plasma Fractionation Facilities in Asia
This week, the Process Development Forum talks to Dr. Neil Goss, an international consultant in biotechnology and plasma fractionation, past director of Research and Development at CSL BioPlasma, Aust…
Article
CDMOs Driving Emerging Bio/Pharma Success
It would take at least two years before that infrastructure could start making product, and much of that capacity would be underutilized. In short, the presence of a robust CDMO industry probably redu…
Article
Going Viral
…n, prefabricated modular manufacturing facility for these therapies, and then rapidly add production capacity to meet demand.
Learn more how viral vector manufacturing can be scaled up.